medical Class II Updated 2021-09-08

Versea Diagnostics LLC recalls Status COVID-19/Flu Rapid Immunoassay for Direct Detection a

Recalled Product

Status COVID-19/Flu Rapid Immunoassay for Direct Detection and Differential Diagnosis of SARS-CoV-2, Influenzas Type A, and Type B Antigens Simultaneous qualitative detection and differentiation of nucleocapsid antigen from SARS-CoV-2, influenza A and influenza B directly from nasopharyngeal swab specimens obtained from individuals, who are suspected of respiratory viral infection consistent with COVID-19 by their healthcare provider, within the first five days of onset of symptoms. Emergency use of this test is limited to authorized laboratories. (CLIA Waived Laboratories)


Hazard / Issue

Products may have been distributed to customers other than laboratories certified under the Clinical Laboratory Improvement Amendments as stipulated in the Emergency Use Authorization.

Issued by

FDA

Distribution: Nationwide (United States)
Lot/Code Info: all lot codes
View official government recall

Looking for safe alternatives?

Browse certified-safe products in this category on Amazon →